Peter Marks

Company: FDA
Job title: Director, CBER
Seminars:
Virtual: Rare Disease Gene Therapy Development: Where Has It Been and Where Is It Going? 8:30 am
Comparing progress in rare disorders in vivo with developments seen in CAR-T and ex vivo cell modified gene therapies Where are the current bottlenecks for gene therapy approvals? Addressing FDA’s outlook for gene therapy in 2022Read more
day: Day One